Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations.
- What is known about the combination of PARP inhibitors and abiraterone acetate plus prednisone in the treatment of patients with metastatic prostate cancer? (00:17-01:40)
- What were the aims, design and inclusion criteria of the MAGNITUDE study? (01:40-03:13)
- What were the efficacy and safety findings of the study and how did they differ in the cohorts with and without DNA repair defects? (03:14-06:09)
- What will be the challenges of incorporating PARP inhibitors into clinical practice in this patient population? (06:09-07:36)
Speaker Disclosure: Kim Chi discloses consultancy services for: Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Macrogenics, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He discloses grant/research support from: Astellas, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He is a member of the advisory board for: Astellas, Astra Zeneca, Janssen, Merck, Novartis and Roche. He has received honoraria/honorarium from: AstraZeneca, Janssen and Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022
Share this Video
Related Videos In Genitourinary Cancer
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Kim Chi, ASCO GU22: First Results of the Phase III MAGNITUDE Study
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations. Abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012 Questions What is […]
Simon Crabb, ASCO GU22: Final Analysis of the ATLANTIS Rucaparib Arm Assessing PARP Inhibitors for Metastatic Urothelial Carcinoma
touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma. Questions What is the rationale for the use of PARP inhibitors in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!